Incorporating KRAS as a novel biomarker: Challenges and opportunities
Incorporating KRAS as a novel biomarker: Challenges and opportunities
Real world data and diagnostics in patients with NSCLC with EGFR exon 20 insertions
Durvalumab following radiotherapy in patients with unresectable, stage 3 NSCLC ineligible for chemotherapy
Cancer Genomics in Africa today
OncoAlert and ecancer weekly roundup for March 01 - 06, 2021
Challenges and solutions in PD-L1 testing in NSCLC
Managing immune-related adverse events
ERAS in gynaecological oncology from developed to developing countries
Managing the treatment of NSCLC patients during the COVID-19 pandemic (DE)
Oral HIF-2 α inhibitor MK-6482 in patients with advanced clear cell renal cell carcinoma
SEMS trial: result of a prospective, multi-institutional phase II clinical trial of surgery in early metastatic seminoma
Sequencing endocrine treatment in metastatic luminal breast cancer and alpelisib for treatment of metastatic BC